

## West of Scotland Cancer Network

### Urological Cancers MCN Work Plan 2023/2024

	Actions Required	Lead	Due Date
<b>1.</b>	<b>Continue to engage with the Regional MDT Improvement Programme to optimise operational efficiency and effectiveness of the MDT</b>		
1.1	Work with MDT programme Board and eHealth colleagues to progress development of the MDT system utilising the agreed core dataset for renal, bladder, testicular, penile and prostate cancers.	MCN Clinical Lead MCN Manager	Ongoing  In line with regional programme.
1.2	Agree actions arising from the MDT FIT QA process and engage with local MDTs to deliver against these.	MDT-FIT Project Facilitator Local MDT Leads / members	
<b>2.</b>	<b>Support after Treatment: Risk Stratified Follow Up</b>		
2.1	Facilitate ongoing regional roll out of the remote digital platform [Connect Me] for follow up of radically treated prostate cancer patients (post-radical prostatectomy or radical radiotherapy) <ul style="list-style-type: none"> <li>Expand Go live in NHSAA and share learning</li> <li>Roll out to NHSGGC, NHS Lanarkshire, NHS Forth Valley</li> </ul>	LWC Clinical Lead  MCN Manager  NSS Team	April 23  In line with national/local ehealth teams
2.2	Participate in National Single Point of Contact (SPoC) Forum to share learning from the 12 funded pilot projects <ul style="list-style-type: none"> <li>Collate data to enable evaluation of service and patient experience of new method of follow up</li> </ul>	Local e health Teams	Ongoing
2.3	Scope areas for future expansion, notably in Germ Cell Tumours. <ul style="list-style-type: none"> <li>Work with NHSNSS and key stakeholders to define the IT specification.</li> </ul>		December 23
<b>3.</b>	<b>Patient Reported Outcome Measures (PROMs)</b>		
3.1	Support delivery of the regional PROMs workplan as required as outlined in the overarching regional workplan actions aligned under Patient Centred Care for All.	MCN Clinical Lead MCN Manager	Ongoing
3.2	For prostate cancer patients, support implementation of PROMs collection for radical radiotherapy and radical brachytherapy based on the system currently in place for radical prostatectomy patients and which is reported via the National QPIs (QPI 8).	MCN Advisory Board Regional Prostate Service BWoSCC Radiotherapy and Brachytherapy Services	July 23
3.3	Support development and regional implementation of a new system for electronic collection and reporting of PROMs in the three identified cohorts of radically treated prostate cancer patients.		July 23 onwards

<b>4. Develop and maintain regional /national guidelines to optimise patient care</b>			
4.1	<p>Co-ordinate the review of clinical management guidelines (CMGs) and clinical guidance documents (CGDs) in line with WoSCAN SOPs.</p> <p><b>CMGs</b></p> <ul style="list-style-type: none"> <li>• Prostate Cancer</li> <li>• Metastatic Renal Cancer</li> <li>• Non metastatic Renal cancer</li> <li>• Bladder Cancer</li> <li>• Urothelial Cancer</li> </ul> <p><b>CGDs</b></p> <ul style="list-style-type: none"> <li>• Bladder Cancer Follow up</li> <li>• Renal Cancer Follow Up</li> </ul>	<p>MCN Clinical Lead</p> <p>Oncology Lead</p> <p>MCN Manager</p>	<p>December 23</p> <p>July 23</p> <p>June 23</p> <p>August 23</p> <p>June 23</p> <p>On publication of National Bladder Cancer surveillance pathways.</p> <p>December 23</p>
<b>5. Maintain tumour specific regional service configuration maps</b>			
5.1	Update audit data annually in line with QPI report publication schedule.	MCN Manager	<p>On publication of QPI reports:</p> <p>Renal</p> <p>Bladder</p> <p>Testes</p> <p>Prostate</p>
<b>6. Deliver regional education event which facilitates review of clinical audit data as required, and promotes shared learning of current best practice and innovation.</b>			
6.1	Development of a focused programme for the event, addressing relevant key issues.	MCN Clinical Lead/ MCN Manager	Q2 24
6.2	<p>Establish data requirements for the event, and any arising as a result of the event.</p> <ul style="list-style-type: none"> <li>• Liaise with information team regards audit presentation requirements</li> <li>• Liaise with information team if any further audit opportunities identified</li> <li>• Ensure appropriate data sharing agreements issued, completed, agreed and passed to information team</li> </ul>	MCN Manager	
6.3	<p>Develop action plans arising from event. Monitor progress of agreed actions.</p> <ul style="list-style-type: none"> <li>• Record actions arising from discussion at event</li> <li>• Develop action plans of same</li> <li>• Issue action plans as appropriate</li> <li>• Monitor progress of actions recorded</li> </ul>	MCN Manager	

<b>7. Use of clinical data to drive improvement in quality of care and outcomes</b>			
7.1	<p>Review individual tumour specific QPI audit findings to identify variation in practice and highlight exceptions.</p> <ul style="list-style-type: none"> <li>• Performance Summary Returns Assessed</li> <li>• RCOG exception reports produced</li> <li>• Governance review and Interrogation of QPI exceptions</li> <li>• Agreement of actions for inclusion in annual audit reports</li> <li>• Input to the production of individual urological cancers tumour specific Annual Clinical Audit Reports</li> </ul>	MCN Clinical Lead Information Manager MCN Manager	April 23
7.2	Identify requirements for further data analysis to aid understanding of variance, and develop actions/ improvement plans or focussed audit.	MCN Clinical Lead MCN Manager	As per reporting schedule above
7.3	<p>Monitor and ensure progress with regional and local board action/improvement plans.</p> <ul style="list-style-type: none"> <li>• Conclusion of actions from QPI Exception Reports for bladder, prostate, renal and testicular cancer</li> </ul>	MCN Clinical Lead MCN Manager Board Clinical Effectiveness Leads RCOG	Action plans to be returned within 2 months of publication.
7.4	<p>Re-audit and report outcomes of 2021 upper tract TCC audit data to ensure equity of care in the region.</p> <ul style="list-style-type: none"> <li>• Comparison with 2019 data</li> <li>• Action any variance as required.</li> </ul>	MCN Manager/ Renal MDT members/MCN Clinical Lead	March 24
7.5	<p>Expand on regional analysis and comparison of treatment types in prostate cancer patients.</p> <ul style="list-style-type: none"> <li>• Review and report national comparison supplementing prostate QPI data</li> </ul>	MCN Advisory Board	March 24
7.6	Audit of Renal Follow up diagnostics to inform regional follow up guidance.	MCN Advisory Board	March 24
<b>Watching Brief</b>			
Maintain watching brief on development of a national digital solution for Treatment Summaries			
Continue to work with Regional Planning colleagues to deliver the actions identified as part of the ongoing WoS Urology Services Review.			